SOURCE: Immunotech Laboratories Inc.
PASADENA, CA--(Marketwire - Mar 1, 2013) - Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has relocated to a new Research & Development Lab facility in Monrovia, California.
The new facility incorporates more laboratory use of the actual facility than the combined Administrative space at the previous Pasadena location. The new location also is geographically more conveniently located for the Immunotech team.
In light of the recent announcements stating the HIV-AIDS and Hepatitis C clinical trials using the company's patented "ITV-1" patented technology treatment by the Immunotech BG sister company, more clinical research and results testing is necessary. The new facility accommodates the additional lab space.
Utilizing a combination of the clinical tests and results being conducted in Bulgaria alongside the results analysis here in the USA at the new facility, Immunotech plans to submit all the results from the Bulgarian clinical trials for US Food & Drug Administration "FDA" approval on a pre IND meeting. Immunotech Laboratories plans to start working with IND Directions, LLC (http://inddirections.com)
Immunotech's ultimate goal is to provide a worldwide FDA approved treatment for combating the HIV-AIDS virus with the intent of terminating the virus and restoring the immune system. The goal of this treatment is to achieve reduction of resistance of existing therapies on the market.
The clinical trials in Bulgaria (Referred to as EU) are scheduled to begin in May 2013 and end in October 2013, which will give Immunotech, the rights to receive approval for applications of the "IPF" Treatment. In this respect, Immunotech Laboratories BG has had a series of conversations with Mr. Vladimir Stoichev, the Deputy General Director from Sopharma Bulgaria, and the parties have had talks for the possible signing of a contract between Immunotech Laboratories BG and Sopharma for joint production of IPF-ITV.
Sopharma is a leading pharmaceutical company in the European Union.
RELEVANT ARTICLES & LINKS FOR AIDS-HIV MEDICINES
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.